{
    "clinical_study": {
        "@rank": "88935", 
        "arm_group": [
            {
                "arm_group_label": "Normal Hepatic Function (Healthy Volunteers)", 
                "arm_group_type": "Experimental", 
                "description": "Healthy volunteers as defined by an eGFR \u226590 mL/min/1.73mE2 as determined by the estimated glomerular filtration rate (eGFR) from the Modification of Diet in Renal Disease (MDRD) Study will receive a single 33mg/kg oral dose of deferiprone."
            }, 
            {
                "arm_group_label": "Mild Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Mild renal impairment defined as eGFR 60-89 mL/min/1.73mE2 as determined by the estimated glomerular filtration rate (eGFR) from the Modification of Diet in Renal Disease (MDRD) Study will receive a single 33mg/kg oral dose of deferiprone."
            }, 
            {
                "arm_group_label": "Moderate Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Moderate renal impairment as defined by eGFR 30-59 mL/min/1.73mE2 as determined by the estimated glomerular filtration rate (eGFR) from the Modification of Diet in Renal Disease (MDRD) Study will receive a single 33mg/kg oral dose of deferiprone."
            }, 
            {
                "arm_group_label": "Severe Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Severe renal impairment as defined by an eGFR 15-19 mL/min/1.73mE2 as determined by the estimated glomerular filtration rate (eGFR) from the Modification of Diet in Renal Disease (MDRD) Study will receive a single 33mg/kg oral dose of deferiprone."
            }
        ], 
        "brief_summary": {
            "textblock": "Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the\n      effect of impaired renal function on the PK of deferiprone and its 3-O-glucuronide\n      metabolite following a single oral dose of 33mg/kg Ferriprox\u00ae."
        }, 
        "brief_title": "An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate and Severe Renal Impairment and Healthy Volunteers", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Impairment", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "Post-marketing study to evaluate the effect of impaired renal function on the\n      pharmacokinetics (PK) of deferiprone and its 3-O-glucuronide metabolite and on the safety of\n      Ferriprox\u00ae in subjects with mild, moderate and severe renal impairment as compared to\n      healthy volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n        All subjects:\n\n          1. Adult males or females, 18 - 75 years of age (inclusive);\n\n          2. Body weight \u2265 45 kg;\n\n          3. Body mass index (BMI) range of approximately 18.5-32  kg/mE2  (inclusive);\n\n          4. Absolute neutrophil count (ANC) of >1.5x10E9/L;\n\n        Healthy volunteers:\n\n          1. Medically healthy with clinically insignificant screening results (e.g., laboratory\n             profiles, medical history, vital signs, physical examination);\n\n          2. eGFR \u2265 90 mL/min/1.73mE2;\n\n        Renally impaired subjects:\n\n          1. Considered clinically stable in the opinion of the Investigator;\n\n          2. Subjects with mild renal impairment (eGFR 60-89 mL/min/1.73mE2) OR moderate renal\n             impairment (eGFR 30-59 mL/min/1.73mE2) OR severe renal impairment (eGFR 15-29\n             mL/min/1.73mE2).\n\n        Main Exclusion Criteria:\n\n          1. History of renal transplant;\n\n          2. Subjects undergoing any method of dialysis;\n\n          3. History or presence of clinically unstable significant respiratory, cardiovascular,\n             pulmonary, hepatic, renal (except for subjects assigned to one of the renally\n             impaired groups), hematologic, gastrointestinal, endocrine, immunologic,\n             dermatologic, neurologic, or psychiatric disease;\n\n          4. Disorders or surgery of the gastrointestinal tract which may interfere with drug\n             absorption or may otherwise influence the PK of the investigational medicinal product\n             (e.g. cholecystectomy, resections of the small or large intestine, febrile\n             conditions, chronic diarrhea, chronic vomiting, endocrine disease, severe infections,\n             acute inflammations, etc.);\n\n          5. Clinically significant abnormalities on 12-lead ECG (e.g., QTcF\u2265430 ms in males or\n             \u2265450 ms in females);\n\n          6. Evidence of liver damage: hepatitis B and C; aspartate aminotransferase (AST),\n             alanine aminotransferase (ALT) that is considered clinically significant by the\n             Investigator;\n\n          7. Participation in another clinical trial within 28 days prior to the study drug\n             administration;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01770652", 
            "org_study_id": "LA39-0412"
        }, 
        "intervention": {
            "arm_group_label": [
                "Normal Hepatic Function (Healthy Volunteers)", 
                "Mild Renal Impairment", 
                "Moderate Renal Impairment", 
                "Severe Renal Impairment"
            ], 
            "intervention_name": "Deferiprone", 
            "intervention_type": "Drug", 
            "other_name": [
                "Ferriprox", 
                "DFP", 
                "L1"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Deferiprone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Renal Impairment", 
            "Kidney Impairment", 
            "Kidney Disease", 
            "Ferriprox", 
            "Deferiprone", 
            "DFP", 
            "L1"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T2M4"
                    }, 
                    "name": "H\u00f4pital Maisonneuve-Rosemont"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount-Royal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3P3P1"
                    }, 
                    "name": "Algorithme Pharma Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open-label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox in Subjects With Impaired Renal Function and Healthy Volunteers", 
        "overall_official": {
            "affiliation": "ApoPharma", 
            "last_name": "Fernando Tricta, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic parameters will be assessed over a 24 hour interval using blood and urine samples for analyses of deferiprone and its 3-O-glucuronide metabolite in subjects with normal, mild, moderate and severe renal impairment.", 
            "measure": "From serum and urine deferiprone concentration-time profiles: Cmax, Tmax, AUC0-t,AUC0-\u221e ,T\u00bd , CL/F,,CLr, Vd/F, Ae, Fe. From serum and urine deferiprone 3-O-glucuronide concentration-time profiles: Cmax, Tmax, AUC0-t, AUC0-\u221e, T\u00bd, CLr, Ae.", 
            "safety_issue": "No", 
            "time_frame": "Prior to dosing and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 9, 12, 16 and 24 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01770652"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety and tolerability will be assessed based on changes in: physical examinations, vital signs, 12-lead ECG, clinical laboratory tests, use of concomitant medication and frequency of adverse events (AEs) following a single dose of Ferriprox.", 
            "measure": "Safety and tolerability of Ferriprox\u00ae in subjects with renal impairment.", 
            "safety_issue": "Yes", 
            "time_frame": "Prior to dosing until 72 hours post-dose"
        }, 
        "source": "ApoPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ApoPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}